Share Twitter LinkedIn Facebook Email Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib doing patterns and the data presented for appropriate dosing of Carfilzomib at the 2017 American Society of Hematology.
ASH 2025 MDS/ALL Highlights: Verona Trial Lessons & CLEVER Pathway | Dr. Jeyakumar Acute Lymphoblastic Leukemia 5 Mins Read
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read